Epitope characterization of the ADA response directed against a targeted immunocytokine

Journal of Pharmaceutical and Biomedical Analysis

Volumn 114, Issue , 2015, Pages 296-304

  Stubenrauch, Kay ^a   Künzel, Christian ^a   Vogel, Rudolf ^a   Tuerck, Dietrich ^b   Schick, Eginhard ^b   Heinrich, Julia ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Anti drug antibody epitope characterization; Domain competition assay; Domain detection assay; Immunogenicity testing; Multi domain biotherapeutic; Targeted immunocytokine

Indexed keywords

DRUG ANTIBODY; EPITOPE; IMMUNOCYTOKINE; TARGETED IMMUNOCYTOKINE; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ACCURACY; ADULT; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTION; FALSE POSITIVE RESULT; FEMALE; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; LIMIT OF DETECTION; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ANIMAL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; BINDING COMPETITION; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; PROCEDURES; PROTEIN TERTIARY STRUCTURE; REPRODUCIBILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BINDING, COMPETITIVE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MALE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84934998472     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.05.029     Document Type: Article

References (20)

1. Xiang J. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins. Hum. Antibodies 1999, 9:23-36.
2. Pasche N., Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov. Today 2012, 17:583-590.
3. Sondel P.M., Gillies S.D. Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies (Basel) 2012, 1:149-171.
4. List T., Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin. Pharmacol. 2013, 20:29-45.
5. Gorovits B., Wakshull E., Pillutla R., Xu Y., Manning M.S., Goyal J. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J. Immunol. Methods 2014, 408:1-12.
6. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1-9.
7. Shankar G., Pendley C., Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 2007, 25:555-561.
8. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1-16.
9. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267-1281.
10. Stubenrauch K., Wessels U., Vogel R., Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal. Biochem. 2009, 390:189-196.
11. Hoofring S.A., Lopez R., Hock M.B., Kaliyaperumal A., Patel S.K., Swanson S.J., Chirmule N., Starcevic M. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis 2013, 5:1041-1055.
12. Staack R.F., Stracke J., Stubenrauch K., Vogel R., Schleypen J., Papadimitriou A. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. Bioanalysis 2011, 3:523-534.
13. Stubenrauch K., Wessels U., Lenz H. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. J. Pharm. Biomed. Anal. 2009, 49:1003-1008.
14. US Food and Drug Administration, Guidance for industry: assay development for immunogenicity testing of therapeutic proteins (draft guidance), Published as a Notice in the Federal Register, 74 Fed. Reg. 63,758, December 4, 2009 (Docket No. FDA-2009-D-0539).
15. Committee for medical Products for Human Use, Guideline on the immunogenicity assessment of biotechnology-derived therapeutic proteins, Doc. Ref. EMEA/CHMP/BMWP/14327/2006, London, 2007.
16. Committee for medical Products for Human Use, Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Doc. Ref. EMA/CHMP/BMWP/86289/2010, London, 2012.
17. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., Gupta S., Herzyk D., Hurst C., Ivens I.A., Kawabata T., Maier C., Mounho B., Rup B., Shankar G., Smith H., Thomas P., Wierda D. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 2009, 54:164-182.
18. Tatarewicz S.M., Juan G., Swanson S.J., Moxness M.S. Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J. Immunol. Methods 2012, 382:93-100.
19. Ben-Horin S., Yavzori M., Katz L., Kopylov U., Picard O., Fudim E., Coscas D., Bar-Meir S., Goldstein I., Chowers Y. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011, 60:41-48.
20. Jacobsen F.W., Padaki R., Morris A.E., Aldrich T.L., Armitage R.J., Allen M.J., Lavallee J.C., Arora T. Molecular and functional characterization of cynomolgus monkey IgG subclasses. J. Immunol. 2011, 186:341-349.